- Home
- BRY vs VNDA Comparison
BRY vs VNDA Comparison
Compare BRY & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRY
- VNDA
- Stock Information
- Founded
- BRY 1909
- VNDA 2002
- Country
- BRY United States
- VNDA United States
- Employees
- BRY N/A
- VNDA N/A
- Industry
- BRY Oil & Gas Production
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- BRY Energy
- VNDA Health Care
- Exchange
- BRY Nasdaq
- VNDA Nasdaq
- Market Cap
- BRY 313.9M
- VNDA 270.0M
- IPO Year
- BRY N/A
- VNDA 2006
- Fundamental
- Price
- BRY $4.01
- VNDA $4.55
- Analyst Decision
- BRY Hold
- VNDA Strong Buy
- Analyst Count
- BRY 1
- VNDA 2
- Target Price
- BRY $5.00
- VNDA $15.50
- AVG Volume (30 Days)
- BRY 1.6M
- VNDA 637.3K
- Earning Date
- BRY 11-07-2024
- VNDA 02-05-2025
- Dividend Yield
- BRY 18.68%
- VNDA N/A
- EPS Growth
- BRY 73.42
- VNDA N/A
- EPS
- BRY 1.06
- VNDA N/A
- Revenue
- BRY $806,733,000.00
- VNDA $190,858,000.00
- Revenue This Year
- BRY N/A
- VNDA $5.60
- Revenue Next Year
- BRY N/A
- VNDA $42.85
- P/E Ratio
- BRY $3.72
- VNDA N/A
- Revenue Growth
- BRY N/A
- VNDA N/A
- 52 Week Low
- BRY $3.87
- VNDA $3.46
- 52 Week High
- BRY $8.88
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- BRY 44.24
- VNDA 38.80
- Support Level
- BRY $3.87
- VNDA $4.51
- Resistance Level
- BRY $4.39
- VNDA $4.95
- Average True Range (ATR)
- BRY 0.17
- VNDA 0.18
- MACD
- BRY 0.05
- VNDA -0.04
- Stochastic Oscillator
- BRY 53.85
- VNDA 12.50
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.